CN103906518B - 使用ras拮抗剂的恶性的和非恶性的疾病治疗 - Google Patents

使用ras拮抗剂的恶性的和非恶性的疾病治疗 Download PDF

Info

Publication number
CN103906518B
CN103906518B CN201280048941.1A CN201280048941A CN103906518B CN 103906518 B CN103906518 B CN 103906518B CN 201280048941 A CN201280048941 A CN 201280048941A CN 103906518 B CN103906518 B CN 103906518B
Authority
CN
China
Prior art keywords
ras
cell proliferation
malignant
proliferation
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280048941.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103906518A (zh
Inventor
小詹姆斯·H·威克尔
迈克尔·J·布朗斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PISCES THERAPEUTICS LLC
Original Assignee
PISCES THERAPEUTICS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PISCES THERAPEUTICS LLC filed Critical PISCES THERAPEUTICS LLC
Publication of CN103906518A publication Critical patent/CN103906518A/zh
Application granted granted Critical
Publication of CN103906518B publication Critical patent/CN103906518B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201280048941.1A 2011-10-07 2012-10-05 使用ras拮抗剂的恶性的和非恶性的疾病治疗 Expired - Fee Related CN103906518B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544471P 2011-10-07 2011-10-07
US61/544,471 2011-10-07
PCT/US2012/058900 WO2013052765A1 (en) 2011-10-07 2012-10-05 Malignant and non-malignant disease treatment with ras antagonists

Publications (2)

Publication Number Publication Date
CN103906518A CN103906518A (zh) 2014-07-02
CN103906518B true CN103906518B (zh) 2020-03-13

Family

ID=48044179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280048941.1A Expired - Fee Related CN103906518B (zh) 2011-10-07 2012-10-05 使用ras拮抗剂的恶性的和非恶性的疾病治疗

Country Status (11)

Country Link
US (1) US9309203B2 (https=)
EP (1) EP2763681B1 (https=)
JP (1) JP6165744B2 (https=)
CN (1) CN103906518B (https=)
AU (1) AU2012318471B9 (https=)
CA (1) CA2849421C (https=)
ES (1) ES2642843T3 (https=)
IL (1) IL231757A (https=)
MX (1) MX364551B (https=)
RU (1) RU2632097C2 (https=)
WO (1) WO2013052765A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
CN103304499B (zh) * 2013-06-02 2015-03-04 张远强 抗糖尿病化合物、其制备方法和用途
CN103304500B (zh) * 2013-06-02 2015-03-04 张远强 新型抗糖尿病化合物、其制备方法和用途
CN103304501B (zh) * 2013-06-02 2015-03-04 张远强 一类抗糖尿病化合物、其制备方法和用途
CN103304498B (zh) * 2013-06-02 2015-03-04 张远强 一种抗糖尿病化合物、其制备方法和用途
CN103304503B (zh) * 2013-06-02 2015-03-04 张远强 抗糖尿病化合物、其制备方法和用途
KR20160091920A (ko) 2013-11-18 2016-08-03 예일 유니버시티 트랜스포존 조성물 및 이의 이용 방법
WO2016056606A1 (ja) * 2014-10-07 2016-04-14 国立大学法人京都大学 ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品
JP6875745B2 (ja) * 2016-02-16 2021-05-26 国立大学法人大阪大学 線維化を治療するための医薬組成物
TR201920922A2 (tr) * 2019-12-20 2020-06-22 Ankara Ueniversitesi 3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078303A1 (en) * 1999-06-18 2000-12-28 Thyreos Corporation Non-malignant disease treatment with ras antagonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107587A (en) 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
AU4723897A (en) * 1996-10-24 1998-05-15 Kyowa Hakko Kogyo Co. Ltd. 1,4-benzoquinone derivatives
JP2001513890A (ja) 1997-02-26 2001-09-04 サイレオス コーポレーション リポタンパク質の膜アンカーを標的とする薬剤スクリーニング法
GEP20043214B (en) * 1999-01-21 2004-04-26 Bristol Myers Squibb Company Us Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same
US20050119237A1 (en) 1999-06-18 2005-06-02 Ramot University Authority For Applied Research & Industrial Development Ltd. Non-malignant disease treatment with Ras antagonists
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
US20070054886A1 (en) 2003-05-23 2007-03-08 Ramot At Tel Aviv University, Ltd. Ras antagonists for treating neurodegenerative disorders
ES2414861T3 (es) * 2004-08-18 2013-07-23 Kadmon Corporation, Llc Uso del FTS para el tratamiento de trastornos malignos
WO2007064448A2 (en) 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
EP1986625B1 (en) 2006-02-10 2012-08-01 Ramot at Tel-Aviv University Ltd. Treatment of ovarian cancer
CA2648518C (en) 2006-04-11 2012-06-26 Ramot At Tel Aviv University Ltd. Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
WO2007144889A2 (en) 2006-06-14 2007-12-21 Ramot At Tel Aviv University Ltd. Treatment of neurofibromatosis
WO2008075342A1 (en) 2006-12-19 2008-06-26 Ramot At Tel Aviv University Ltd. Treatment of lung cancer
WO2009048541A2 (en) * 2007-10-05 2009-04-16 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
US8338481B2 (en) * 2009-01-28 2012-12-25 Ramot At Tel-Aviv University Ltd. Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078303A1 (en) * 1999-06-18 2000-12-28 Thyreos Corporation Non-malignant disease treatment with ras antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Minimal Structural Requirements for Diglyceride-Site Directed Activators of Protein Kinase C;Michal Marom 等;《Tetrahedron》;19971231;第53卷(第29期);10041-10050 *

Also Published As

Publication number Publication date
RU2014118430A (ru) 2015-11-20
JP6165744B2 (ja) 2017-07-19
IL231757A0 (en) 2014-05-28
US20140249163A1 (en) 2014-09-04
CA2849421A1 (en) 2013-04-11
MX364551B (es) 2019-04-30
EP2763681B1 (en) 2017-08-16
EP2763681A4 (en) 2015-04-15
AU2012318471B2 (en) 2017-05-04
JP2014528453A (ja) 2014-10-27
AU2012318471A1 (en) 2014-05-22
EP2763681A1 (en) 2014-08-13
AU2012318471B9 (en) 2017-06-01
MX2014004126A (es) 2014-07-28
ES2642843T3 (es) 2017-11-20
CA2849421C (en) 2020-04-28
WO2013052765A1 (en) 2013-04-11
IL231757A (en) 2017-07-31
US9309203B2 (en) 2016-04-12
CN103906518A (zh) 2014-07-02
RU2632097C2 (ru) 2017-10-02

Similar Documents

Publication Publication Date Title
CN103906518B (zh) 使用ras拮抗剂的恶性的和非恶性的疾病治疗
TWI352084B (en) Gsk-3 inhibitors
US11578058B2 (en) Heterocyclic compounds for inhibiting TYK2 activities
US20050209195A1 (en) Indolinone derivatives
US20100240716A1 (en) Thiadiazoline derivative
JPWO2007142323A1 (ja) 側鎖にスピロ環構造を有する新規インダゾール誘導体
US20190322625A1 (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
US20250074904A1 (en) Nsd2-targeted checmical degraderts and compositions and methods of use thereof
US20120295917A1 (en) Imatinib dichloroacetate and anti-cancer agent comprising the same
WO2023011312A1 (zh) 多取代噻唑衍生物及其在疾病治疗中的应用
US9738614B2 (en) Malignant and non-malignant disease treatment with Ras antagonists
US20060229324A1 (en) Quinazolin-4-one derivatives
US20190330142A1 (en) Inhibitors of mtor-deptor interactions and methods of use thereof
US11274074B2 (en) Pharmaceutical composition for ANO1 antagonist with anticancer activity
CN101193878A (zh) 实体肿瘤治疗剂
WO2023217184A2 (zh) 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途
Class et al. Patent application title: INHIBITORS OF MTOR-DEPTOR INTERACTIONS AND METHODS OF USE THEREOF
US20260092038A1 (en) Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
WO2025240834A1 (en) Nsd2-targeted chemical degraders and compositions and methods of use thereof
CN103172619B (zh) 4-(取代苄基)-1(2h)-2,3-二氮杂萘酮类衍生物及其制备方法、药物组合物和用途
HK40122921A (zh) 大麻素受体1拮抗剂/反向激动剂及其用途
CN103172619A (zh) 4-(取代苄基)-1(2h)-2,3-二氮杂萘酮类衍生物及其制备方法、药物组合物和用途
HK1100426B (en) Thiadiazolidinones as gsk-3 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200313

Termination date: 20211005

CF01 Termination of patent right due to non-payment of annual fee